BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1) — BONAPH1DE

Primary Hyperoxaluria Type 1 Clinical Trial

Official title:
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)

Status Recruiting

Clinical Trial Summary

The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04982393
Study type	Observational
Source	Alnylam Pharmaceuticals
Contact	Alnylam Clinical Trial Information Line
Phone	1-877-ALNYLAM
Email	clinicaltrials@alnylam.com
Status	Recruiting
Phase
Start date	December 13, 2021
Completion date	September 2028

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Completed	`NCT02830009` - IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA	N/A
Terminated	`NCT02795325` - A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)	Phase 1
Completed	`NCT03067142` - Proteomics of Primary Hyperoxaluria Type 1
Active, not recruiting	`NCT04152200` - A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1	Phase 3
Recruiting	`NCT05001269` - Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function	Phase 2
Recruiting	`NCT04580420` - Safety & Efficacy of DCR-PHXC in Patients With PH1/2 and ESRD	Phase 2